Research conducted in collaboration with IPF experts and the Pulmonary Fibrosis Foundation reveals critical gaps in diagnosis, treatment, and quality of life for people living with IPF Findings ...

The Pulmonary Fibrosis Foundation's Care Center Network has grown to include 96 sites in 40 states as part of its first expansion since 2023, marking a milestone in strengthening access to ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease that causes scarring (fibrosis) of the lungs. The most common symptoms are shortness of breath and cough, and the ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. There are only three therapies for IPF approved by the ...

Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for ...

Mendelian randomization revealed a potential protective role of IPF against large artery atherosclerosis stroke, but no significant links with other cardiovascular diseases. The study suggests ...

Randomized, placebo-controlled study to evaluate safety, tolerability, and potential for positive impact on lung functionAUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") ...

If you have scarring in your lungs, you may have been diagnosed with pulmonary fibrosis. When the reason for this scarring is unknown, your condition is called idiopathic pulmonary fibrosis (IPF). You ...